Using a yeast model of Alzheimer’s disease (AD), Whitehead Institute researchers have identified a drug that reduces levels of the toxic protein fragment amyloid-β (Aβ) and prevents at least some of the cellular damage caused when Ab accumulates in the brains of AD patients.
A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check – for more than two years, in some cases – in many patients with advanced melanoma, according to a new study that provides the longest-term look so far at how melanoma patients have fared since receiving the drug, nivolumab, in a Phase 1 clinical trial.
The Generic Pharmaceutical Association (GPhA) hosted a Congressional briefing highlighting the economic impact and serious dangers to millions of American patients if the Food and Drug Administration’s (FDA) proposed rule on prescription labeling is implemented as drafted.
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart InfectionsMarch 4, 2014 1:28 pm | by Lawrence Berkeley National Laboratory | News | Comments
A team of researchers led by Berkeley Lab scientists have explored, for the first time, how individual Staphylococcus cells glom onto metallic nanostructures of various shapes and sizes that are not much bigger than the cells themselves. Their work could lead to a more nuanced understanding of what...
Exciting research suggests that a shot every one to three months may someday give an alternative to the daily pills that some people take now to cut their risk of getting HIV. The experimental drug has only been tested for prevention in monkeys, but it completely protected them from infection in two studies reported at an AIDS conference on Tuesday.
Sunovion Pharmaceuticals and Takeda Pharmaceutical International announced the results from a double-blind, placebo-controlled study that evaluated the efficacy, safety and tolerability of lurasidone for the maintenance treatment of adults with schizophrenia. Lurasidone is a once-daily oral atypical antipsychotic indicated for the treatment of adults with schizophrenia and is currently available in the United States, Canada and Switzerland.
Actavis confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg. Actavis' ANDA product is a generic version of Sanofi's Multaq, which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF.
There have been great expectations regarding the production of a drug to block the enzyme LTA4 hydrolase, which plays a key role in the body's inflammatory response. However, in clinical trials, such molecules have proven to be only moderately effective. Now, researchers have successfully refined their understanding of why previous substances have been less effective—and in so doing have produced a molecule that gets around the problem.
ProBioGen AG and Merus B.V. signed a non-exclusive commercial option and license agreement on ProBioGen’s GlymaxX fucose-engineering technology. Under the terms of the agreement, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead products, a bispecific anti-cancer antibody.
European Contract Research Organization (CRO), KCR, which is already operating across 18 countries in Europe as well as the U.S., has recently registered new entities in the UK and Germany. This move is part of the company’s strategy to bring the business closer to Western European customers and further deepen client relationships.
Dateline City: NEW YORK NEW YORK--( BUSINESS WIRE )--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par...
Takeda Pharmaceutical announced that the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) have recognized Takeda as a Nadeshiko Brand, a listed enterprise that is “exceptional in encouraging women’s success in the workplace.”
Hamilton Storage Technologies launched the LabElite line of benchtop devices, offering laboratories a a way to automatically process and track samples while ensuring sample integrity. LabElite devices quickly process all common labware types, providing a flexible solution for optimizing workflows.
Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. The study demonstrated that tiotropium Respimat improved lung function and was well tolerated in patients with asthma who remain symptomatic while receiving low-dose maintenance ICS treatment.
Roche announced that an independent data monitoring committee has recommended that the phase 3 METLung study be stopped due to a lack of clinically meaningful efficacy. The study evaluated if onartuzumab (MetMab) in combination with Tarceva (erlotinib) helped patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose tumors were identified as MET-positive live longer compared to Tarceva alone.